–
[비즈월드] Yuhan Corporation’s’Recraza (ingredient name Lasertinib)’ was named as the 31st new drug in Korea.
Yuhan Corporation announced on the 18th that the third-generation target anticancer drug, Rekraza, was approved by the Ministry of Food and Drug Safety.
Recraza is a new drug that Yuhan introduced in the preclinical stage in 2015. Yuhan Corp. obtained this approval after importing new drug candidates, material optimization, process development, preclinical and clinical trials.
Rekraza is an epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer treatment. Resistant to T790M mutation resistance.
In particular, since it can pass through the blood-brain-barrier (BBB), it has excellent efficacy and excellent tolerability even for lung cancer patients with brain metastases. In addition, the possibility of side effects is low, and can be taken by mouth at a certain time every day, regardless of meals.
With this approval, Rekraza can be used to treat patients with T790M mutation-positive locally advanced or metastatic non-small cell lung cancer who are resistant to the first and second generation EGFR target treatments.
In addition, Yuhan Corporation will have the second new drug after’Revanex (ingredient name Revaprazan)’, which was approved in September 2005. In July 2018, Recraza became a new drug in Korea in three years after HK Innoen (formerly CJ Healthcare)’s K-Cap tablet (ingredient name Tegoprazan), a gastroesophageal reflux disease drug.
Lee Jung-hee, CEO of Yuhan Corporation, said, “Recraza is an innovative new drug born with Yuhan’s new drug development capabilities and the dedication of domestic researchers, and a domestic new drug that has received hot interest and positive medical evaluation from the development stage.” “We can provide new treatment options for people.”
– .
